Zolpidem: Uses, Safety and Drug Interactions

Zolpidem: uses, safety and drug interactions

Overview: Zolpidem is a prescription sleep medicine. The information here mainly describes immediate-release zolpidem tartrate tablets in the United States. Extended-release tablets, sprays and sublingual products have different instructions and should not be treated as interchangeable versions of the same prescription.

Uses and formulation: Immediate-release zolpidem is used for the short-term treatment of insomnia involving difficulty falling asleep. Persistent insomnia needs assessment for another physical, mental-health or sleep disorder. The prescription is individualized, and a full night of sleep must remain after taking it. Taking another dose during the same night can increase impairment.

Safety: Sleepwalking, sleep-driving or other activities performed while not fully awake can occur even at recommended doses, sometimes with serious injury. If this happens, do not take another dose and contact the prescriber promptly. Excessive sleepiness, slowed breathing or facial or throat swelling require urgent assessment. Dependence and withdrawal are possible; planned treatment changes should be supervised. Pregnancy and breastfeeding require specific review.

Drug interactions: Alcohol, opioids and other sedating medicines can worsen alertness and breathing risks. Sertraline can increase zolpidem exposure; rifampin can reduce its effect. UK product information also advises against combining it with fluvoxamine or ciprofloxacin. An interaction entry is a reason for professional review, not an instruction to stop a regular medicine yourself. Feeling awake does not guarantee that driving is safe.

Sources

• US prescribing information — zolpidem tartrate immediate-release tablets
• WHO Collaborating Centre ATC/DDD Index 2026 — N05CF02
• Zentiva UK SmPC — Zolpidem Tartrate 5 mg Tablets
• FDA clinical CYP enzyme and transporter interaction examples

This page provides an English summary of the cited sources. Source check: 30 October 2026. This date records a source check, not a clinical review by a doctor or pharmacist. Follow the current leaflet for your product and seek professional advice for personal treatment.